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Objective: We evaluated the correlation between the presence of Chlamydia pneumoniae in atherosclerotic carotid plaques,
lymph nodes, and peripheral blood mononuclear cells (PBMCs), and symptomatic carotid atherosclerotic disease.
Methods: Fifty-one consecutive patients undergoing carotid endarterectomy were enrolled; 18 of the 51 patients had
symptomatic disease, whereas 33 had asymptomatic disease. Detection of C pneumoniae DNA in atherosclerotic carotid
plaques, lymph nodes, and PBMCs was performed with polymerase chain reaction (PCR). C pneumoniae antibodies were
measured with a microimmunofluorescence test.
Results: C pneumoniae DNA in atherosclerotic carotid plaques was detected in 44.4% of patients with symptomatic disease
and in 30.3% of those with asymptomatic disease (P  .48). C pneumoniae DNA in lymph nodes was detected in 33.3%
of patients with symptomatic disease and 18.2% of those with asymptomatic disease (P  .19). Prevalence of C
pneumoniae DNA in PBMCs was significantly higher in patients with symptomatic disease (72.2%) compared with those
with asymptomatic disease (30.3%) (P  .01).
Serologic results support the association between C pneumoniae DNA in PBMCs and symptomatic carotid atheroscle-
rotic disease, because seropositivity for anti-chlamydial immunoglobulin (Ig) A antibodies was significantly higher in
PCR-positive PBMCs in patients with symptomatic disease compared with patients with asymptomatic disease (P .02).
Conclusions: Detection of C pneumoniae in PBMCs shows that C pneumoniae may be associated with symptomatic carotid
atherosclerotic disease. Although we believe there is need for standardization of PCR methods and for assessing
sensitivity, specificity, and predictive values of the tests, we suggest that presence of C pneumoniae DNA in PBMCs is a
valid surrogate marker of risk for endovascular chlamydial infection. Only long-term cohort studies and interventional
trials will clarify the etiopathogenic role of C pneumoniae. (J Vasc Surg 2003;37:1027-31.)
Chlamydia pneumoniae (also called Chlamydophila
pneumoniae) is an obligate intracellular bacterial pathogen
responsible for respiratory tract infection.
In human beings, C pneumoniae is associated with
chronic diseases such as multiple sclerosis,1 Alzheimer dis-
ease,2 lung cancer,3 stroke,4 and coronary heart disease,5
although evidence in lung cancer and stroke is weak and in
multiple sclerosis and Alzheimer disease is controversial.
Involvement of C pneumoniae in the pathogenesis of
atherosclerosis has been supported by findings from sero-
epidemiologic studies, direct detection of chlamydial DNA,
experimental animal and in vitro studies, and antibiotic
intervention trials.
Seroepidemiologic evidence suggests an association be-
tween chronic C pneumoniae infection and atherosclerotic
cardiovascular disease,5-8 although recent studies failed to
demonstrate such a relationship.9,10
C pneumoniae has been detected with polymerase chain
reaction (PCR) assays and immunohistochemistry in arte-
rial atherosclerotic lesions.11 Studies in rabbit and mouse
models indicate that C pneumoniae infection can induce
inflammatory changes similar to those of atherogenesis and
increase progression of atherosclerotic lesions.12,13 In in
vitro studies, C pneumoniae replicated inside a variety of
cell types, including macrophages.14,15
Several therapeutic intervention trials have been per-
formed in patients with established coronary heart dis-
ease.16,17 Results of these studies were encouranging, but
the number of patients was small and the period of fol-
low-up was short.
Other than in vitro studies, confirmation that C pneu-
moniae–infected peripheral blood mononuclear cells
(PBMCs) can be found in vivo has been reported only
recently.18-21
These studies suggest that detection of C pneumoniae
DNA in PBMCs is a useful and appropriate assay that can
enable prediction of vascular infection.
The purpose of our study was to evaluate with PCR the
presence of C pneumoniae in atherosclerotic carotid
plaques, lymph nodes, and PBMCs from patients undergo-
ing carotid endarterectomy. In addition, we examined the
correlation between the presence of C pneumoniae and
symptomatic carotid atherosclerotic disease.
Serologic studies were performed to determine
whether anti–C pneumoniae antibodies are correlated with
symptomatic carotid atherosclerotic disease.
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MATERIAL AND METHODS
Patients
Between May and November 2001, 51 consecutive
patients (37 men, 14 women; mean age, 69  9 years)
undergoing carotid endarterectomy were enrolled. Patients
were classified with symptomatic disease, ie, transient isch-
emic attack or stroke within the past 6 months, or asymp-
tomatic disease, ie, no history of cerebral ischemic event.
Before surgery all patients underwent color flow echo
Doppler imaging, cerebral scanning, transcanial Doppler
scanning, and carotid angiography. Endarterectomy in-
volved a long arteriotomy with dissection of the atheroscle-
rotic lesions in toto. In all patients the degree of carotid
artery stenosis was greater than 70%.
Specimens of lymph nodes, atherosclerotic carotid
plaques, and blood were collected from each patient during
surgery. The inflamed lymph nodes, in front of the carotid
bifurcation, and carotid plaques were removed and stored
immediately at80° C for DNA extraction. Five milliliters
of blood was collected in tubes containing ethylenediami-
netetraacetic acid (EDTA) for isolation of PBMCs and
serologic analysis.
Patient characteristics were as follows: 36 (70.6%) were
current or past smokers, 19 (37.2%) had diabetes, 43
(84.3%) had hypertension, 12 (23.5%) had dyslipidemia, 4
(7.8%) had angina, 11 (21.6%) had acute myocardial infarc-
tion, 10 (19.6%) had transient ischemic attack, and 8
(15.7%) had stroke.
DNA isolation
Lymph nodes and carotid plaques. Frozen tissues
were finely minced and homogenized in a DNA extraction
buffer containing 10 mmol/L of Tris hydrochloride (pH
8.0), 100 mmol/L of EDTA, and 0.5% sodium dodecyl-
sulfate. Proteinase K was added to a final concentration of
100 g/mL. The samples were mixed and incubated at
56° C overnight, followed by 10 min at 98° C. DNA was
isolated from tissues according to the method of Sambrook
et al22 and resuspended in distilled water.
PBMCs. Blood samples were processed to isolate
PBMCs in accordance with a method described by Condos
et al.23 PBMCs were suspended in 40L of ultrapure water
and stored at80° C. PBMCs were centrifuged at 12,000g
for 2 minutes and resuspended in 60L of 10% SDS, 40L
of Tris-EDTA buffer, and 10 L of 20 mg/mL proteinase
K, and were incubated at 56° C for 1 hour, followed by 10
minutes at 98° C.
DNA was isolated from PBMCs according to the
method of Sambrook et al22 and resuspended in 50 L of
distilled water.
Polymerase chain reaction
Genomic C pneumoniae DNA was detected with a
seminested PCR protocol, as described.21 Seminested PCR
was performed with the species-specific HL-1/HR-1
primer pair (438 base pairs) for the first round of 40
amplification cycles.24 The seminested primer pair HM-1/
HR-1, which yields a 229–base pair product, was then used
in the subsequent 40 amplification cycles.24
C pneumoniae DNA-negative samples were analyzed
with PCR for the presence of -globin DNA to confirm the
presence of DNA in the samples. To control for inhibition
of the PCR reaction, a second sample of each specimen was
spiked with target C pneumoniae DNA.
To prevent contamination of samples, reagent prepara-
tion and product analysis were performed in three separate
areas with the use of filter-tipped pipets.
Serologic studies
C pneumoniae antibodies (IgG, IgA) were measured
with a microimmunofluorescence test. Titers of IgG 1:32
or higher and IgA 1:16 or higher were considered positive.
Statistical analysis
Results were subjected to 2 analysis (significance at
P  .05) to compare frequency distribution, with Yates
correction. When the minimum estimated expected value
was less than 5, the Fisher exact test was used.
RESULTS
Overall, 153 tissue specimens (51 lymph nodes, 51
carotid plaques, 51 PBMCs) and 51 blood samples ob-
tained from patients undergoing carotid endarterectomy
were examined for presence of C pneumoniae.
Eighteen of 51 patients examined had symptoms of
cerebral ischemic events in the previous 6 months; 33 did
not.
PCR detection of C pneumoniae. Prevalence of C
pneumoniae DNA in lymph nodes, carotid plaques, and
PBMCs from patients with and without symptomatic dis-
ease is shown in Table I. A higher rate of C pneumoniae
DNA was found in PBMCs (45.1%) than in atherosclerotic
carotid plaques (35.3%) and lymph nodes (23.5%); a statis-
tically significant difference was found between PBMC and
lymph nodes samples (P  .04). In addition, a statistically
significant difference was observed between PBMC PCR
positivity in symptomatic disease and PBMC PCR positivity
in asymptomatic disease (P  .01) (Table I).
The pattern of distribution of C pneumoniae among
patients undergoing carotid endarterectomy is shown in
Table II. C pneumoniae DNA was detected in lymph nodes,
atherosclerotic carotid plaques, and PBMCs in 12 patients;
in atherosclerotic carotid plaques and PBMCs, but not in
lymph nodes, in 6 patients; and in PBMCs only in 5
patients.
The discordant results, PBMC PCR-positive but
plaque PCR-negative, may be due to sensitivity of the assay
of the two different tissues. An additional problem is that in
plaques C pneumoniae organisms tend to cluster.
Serologic detection of C pneumoniae. Microimmu-
nofluorescence studies indicated exposure to C pneu-
moniae in 38 (74.5 %) of 51 patients. C pneumoniae IgG
was found in 37 of 51 patients, 24 of whom were positive
for C pneumoniae IgA. One patient was positive for IgA
without detectable IgG.
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Prevalence of C pneumoniae antibody titers in symp-
tomatic and asymptomatic patients are shown in Table III.
Only C pneumoniae IgG (32)and IgA (16) titers were
significantly associated with symptomatic versus asymp-
tomatic disease (P  .009 for IgG, P  .03 for IgA).
PCR findings in lymph nodes, carotid plaques, and
PBMCs are compared with C pneumoniae IgG and IgA
antibodies in Table IV. A statistically significant associa-
tion was observed between seropositivity to C pneu-
moniae and C pneumoniae DNA in lymph nodes (P 
.01 for IgG, P  .016 for IgA), carotid plaques (P 
.0006 for IgG, P  .006 for IgA), and PBMCs (P 
.0002 for IgG, P  .00005 for IgA).
Anti-chlamydial high IgA titers were associated only
with C pneumoniae DNA in PBMCs (P .007); no corre-
lation was found in all other cases involving high IgA and
IgG titers (Table IV).
In addition, anti-chlamydial IgA titers (16) were
associated with PBMC PCR positivity in symptomatic dis-
ease versus PBMC PCR positivity in asymptomatic disease
(P  .02).
No significant association was observed between car-
diovascular risk factors and C pneumoniae DNA detection
or seropositivity, as shown in Table V.
DISCUSSION
To our knowledge, this is the first study to evaluate the
presence of C pneumoniae DNA concurrently in inflamed
lymph nodes, atherosclerotic carotid plaques, and PBMCs
from patients with and without symptomatic carotid ath-
erosclerotic disease.
Prevalence of C pneumoniae DNA was 23.5% in lymph
nodes, 35.3% in atherosclerotic carotid plaques, and 45.1%
in PBMCs. These results support the hypothesis that C
pneumoniae can disseminate systemically via infected mac-
rophages by hematogenous and lymphatic routes.
In our study the high prevalence of C pneumoniae in
PBMCs was associated with symptomatic carotid athero-
sclerotic disease. Prevalence of C pneumoniae DNA in
PBMCs was significantly higher in patients with symptom-
atic disease than in those with asymptomatic disease (P 
.01). Furthermore, serologic results support the association
between C pneumoniae DNA in PBMCs and symptomatic
carotid atherosclerotic disease, because the prevalence of C
pneumoniae IgA 16 or greater was significantly higher in
PBMC PCR-positive symptomatic disease than in asymp-
tomatic disease (P  .02).
C pneumoniae DNA was less frequently detected in
lymph nodes (23.5%) than in atherosclerotic carotid
plaques and PBMCs. The only published study25 on this
topic did not demonstrate any evidence of C pneumoniae
DNA in lymph nodes. Results of that study and ours
suggest that C pneumoniae might be less frequently dissem-
inated to non-atherosclerotic tissues or it does not persist in
these tissues.
The prevalence of C pneumoniae DNA observed in
atherosclerotic carotid plaques in our study was 35.3%.
Similar data were observed by Johnston et al26 (39.6%).
However, reported PCR detection rates of C pneumoniae
DNA in atherosclerotic carotid plaques in patients under-
going carotid endarterectomy vary between 15% and
70%.26-29 These differences might be explained in part by
population differences and focal localization of C pneu-
moniae in vascular tissue.
In our study the high prevalence of C pneumoniae
DNA in PBMCs was 45.1%. A similar rate (46%) was found
by Blasi et al19 in PBMCs from patients undergoing surgery
to treat abdominal aortic aneurysm. As for atherosclerotic
carotid plaques, presence of C pneumoniae DNA in PBMCs
varied between 8.8% and 59% in patients with ischemic
heart disease.18-21,30
These findings show that standardization of the PCR
method is needed. Current PCR methods are in-house
assays with different primers, reaction conditions, methods
of detection, and DNA extraction procedure. Furthermore,
Smieja et al31,32 suggest that repeat testing of the same
specimen increases sensitivity and reliability of a PCR assay,
Table I. Prevalence of C pneumoniae DNA in lymph nodes, carotid plaques, and PBMCs in symptomatic and
asymptomatic atherosclerotic disease
Symptomatic disease
PCR (n  18)
Asymptomatic disease
PCR (n  33)
Total
PCR (n  51)
P*n % n % n %
Lymph nodes 6 33.3 6 18.2 12 23.5 .19
Carotid plaques 8 44.4 10 30.3 18 35.3 .48
PBMCs 13 72.2 10 30.3 23 45.1 .01
PCR, Polymerase chain reaction positive.
*Symptomatic versus asymptomatic disease.
Table II. Pattern of distribution of C pneumoniae
among patients undergoing carotid endarterectomy
PBMCs
Carotid
plaques
Lymph
nodes
Serologic
findings
No. of
patients
Positive Positive Positive Positive* 12
Positive Positive Negative Positive 6
Positive Negative Negative Positive 5
Negative Negative Negative Positive 15
Negative Negative Negative Negative 13
*Defined as IgG 32 or IgA 16.
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particulary for clinical specimens with a low C pneumoniae
concentration.
Although our serologic data reveal that C pneumoniae
antibodies are significantly associated with symptomatic
versus asymptomatic disease, we are still far from ascribing
them as a predictor of symptomatic disease. Controversial
results have been reported for the association between C
pneumoniae DNA and antibodies to C pneumoniae. Several
studies have demonstrated an association between C pneu-
moniae antibodies and PCR results,19,33 whereas others
have failed to demonstrate such an association.20,29
We found a statistically significant association between
the presence of C pneumoniae DNA in lymph nodes, ath-
erosclerotic carotid plaques, PBMCs, and seropositivity to
C pneumoniae. In addition, a statistically significant associ-
ation was observed between C pneumoniae DNA in
PBMCs and high IgA titers (P  .01). These results dem-
onstrate that high anti-C pneumoniae IgA titers may be a
marker for C pneumoniae DNA in PBMCs.
In accord with findings of other authors,19,20,27 we
found no relation between risk factors for cardiovascular
disease and C pneumoniae DNA detection or seropositivity.
In conclusion, detection of C pneumoniae in PBMCs
demonstrates that C pneumoniae may be associated with
symptomatic carotid atherosclerotic disease. Although we
believe there is need for standardization of PCR methods
and for assessing sensitivity, specificity, and predictive val-
ues of the tests, we suggest that C pneumoniae DNA in
PBMCs is a valid surrogate marker to identify individual
risk for endovascular chlamydial infection. Long-term co-
hort studies and interventional trials will be helpful to
clarify the etiopathogenic role of C pneumoniae.
Table III. Prevalence of C pneumoniae antibody titers in symptomatic and asymptomatic disease
Symptomatic disease
(n  18)
Asymptomatic disease
(n  33)
Total
(n  51)
Pn % n % n %
IgG 32 17 94.4 20 60.6 37 72.5 .009
IgG 128 11 61.1 10 30.3 21 41.2 .06
IgA 16 13 72.2 12 36.4 25 49.0 .03
IgA 32 6 33.3 5 15.1 11 21.6 .12
Table IV. Results of C pneumoniae DNA in relation to IgG and IgA anti–C pneumoniae in patients undergoing carotid
endarterectomy
Lymph nodes Carotid plaques PBMCs
PCR
(n  12)
PCR
(n  39)
P
PCR
(n  18)
PCR
(n  33)
P
PCR
(n  23)
PCR
(n  28)
Pn % n % n % n % n % n %
IgG 32 12 100 25 64.1 .01 18 100 19 57.6 .0006 23 100 14 50.0 .0002
IgG 128 5 41.7 16 41.0 .61 11 61.1 10 30.3 .06 13 56.5 8 28.6 .08
IgA 16 10 83.3 15 38.5 .016 14 77.8 11 33.3 .006 19 82.6 6 21.4 .00005
IgA 32 5 41.7 6 15.4 .07 6 33.3 5 15.1 .12 9 39.1 2 0.07 .01
PCR, Polymerase chain reaction positive; PCR, Polymerase chain reaction negative.
Table V. Relation of C pneumoniae seropositivity and C pneumoniae DNA to cardiovascular risk factors in patients
undergoing carotid endarterectomy
Risk factor
Patients Patients
Seropositive*
(n  38)
Seronegative
(n  13)
P
PCR†
(n  23)
PCR
(n  28)
Pn % n % n % n %
Smoker 27 71.0 9 69.2 .58 17 73.9 22 78.6 .95
Hypertension 33 86.8 10 76.9 .32 20 86.9 23 82.1 .47
Diabetes 13 34.2 6 46.1 .33 10 43.4 9 32.1 .59
Dyslipid 10 26.3 2 15.4 .35 7 30.4 4 14.3 .15
PCR, Polymerase chain reaction positive; PCR, polymerase chain reaction negative.
*Defined as IgG 32 or IgA 16.
†Defined as presence of C pneumoniae DNA in lymph nodes, carotid plaques, or peripheral blood mononuclear cells.
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